Chemical: Drug
fenofibrate

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for fenofibrate

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA APOE E2 N/A N/A N/A
No VIP available CA No VIP available APOE E3 N/A N/A N/A
No VIP available CA No VIP available APOE E4 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs11216158 NC_000011.10:g.116840634G>A, NC_000011.9:g.116711350G>A, NG_012021.1:g.1989C>T, NR_126362.1:n.123+4395G>A, rs34382649
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1205 NC_000001.10:g.159682233C>T, NC_000001.11:g.159712443C>T, NG_013007.1:g.7147G>A, NM_000567.2:c.*1082G>A, XM_005244904.1:c.*374G>A, XM_011509207.1:c.*374G>A, rs16955, rs17860476, rs3190272
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1263177 NC_000011.10:g.116819996C>T, NC_000011.9:g.116690712C>T, NG_012044.1:g.8300G>A, rs35785782
C > T
SNP
No VIP available CA VA
rs135543 NC_000022.10:g.46555321T>C, NC_000022.11:g.46159422C>T, NG_012204.1:g.13823T=, NG_012204.1:g.13823T>C, NM_001001928.2:c.-43+7448C>T, NM_001001928.2:c.-43+7448T>C, NM_005036.4:c.-127+7448C>T, NM_005036.4:c.-127+7448T>C, XM_005261653.1:c.-43+7448T>C, XM_005261654.1:c.-40+7448T>C, XM_005261655.1:c.-127+7448T>C, XM_005261655.2:c.-127+7452C>T, XM_006724269.2:c.-124+7452C>T, XM_006724270.2:c.-40+7452C>T, XM_011530239.1:c.-224+7452C>T, XM_011530240.1:c.-227+7452C>T, XM_011530241.1:c.-140+7452C>T, XM_011530244.1:c.-633+7452C>T, XM_011530245.1:c.-449+7452C>T, XR_244379.1:n.181+7448T>C, XR_937869.1:n.189+7452C>T, XR_937870.1:n.188+7452C>T, rs17248110, rs5767347, rs59629438
T > C
SNP
No VIP available CA VA
rs135550 NC_000022.10:g.46553234C>T, NC_000022.11:g.46157339T>C, NG_012204.1:g.11736C=, NG_012204.1:g.11736C>T, NM_001001928.2:c.-43+5361C>T, NM_001001928.2:c.-43+5361T>C, NM_005036.4:c.-127+5361C>T, NM_005036.4:c.-127+5361T>C, XM_005261653.1:c.-43+5361C>T, XM_005261654.1:c.-40+5361C>T, XM_005261655.1:c.-127+5361C>T, XM_005261655.2:c.-127+5369T>C, XM_006724269.2:c.-124+5369T>C, XM_006724270.2:c.-40+5369T>C, XM_011530239.1:c.-224+5369T>C, XM_011530240.1:c.-227+5369T>C, XM_011530241.1:c.-140+5369T>C, XM_011530244.1:c.-633+5369T>C, XM_011530245.1:c.-449+5369T>C, XR_244379.1:n.181+5361C>T, XR_937869.1:n.189+5369T>C, XR_937870.1:n.188+5369T>C, rs57651164, rs5767340
C > T
SNP
No VIP available CA VA
rs1417938 NC_000001.10:g.159684186T>A, NC_000001.11:g.159714396T>A, NG_013007.1:g.5194A>T, NM_000567.2:c.61+29A>T, XM_005244904.1:c.61+29A>T, XM_011509207.1:c.61+29A>T, rs17860483, rs57494723
T > A
SNP
No VIP available No Clinical Annotations available VA
rs1800206 NC_000022.10:g.46614274C>G, NC_000022.11:g.46218377C>G, NG_012204.1:g.72776C>G, NM_001001928.2:c.484C>G, NM_005036.4:c.484C>G, NP_001001928.1:p.Leu162Val, NP_005027.2:p.Leu162Val, XM_005261653.1:c.484C>G, XM_005261654.1:c.484C>G, XM_005261655.1:c.484C>G, XM_005261655.2:c.484C>G, XM_005261656.1:c.484C>G, XM_005261656.2:c.484C>G, XM_005261657.1:c.484C>G, XM_005261658.1:c.484C>G, XM_006724269.2:c.484C>G, XM_006724270.2:c.484C>G, XM_011530239.1:c.484C>G, XM_011530240.1:c.484C>G, XM_011530241.1:c.484C>G, XM_011530242.1:c.484C>G, XM_011530243.1:c.484C>G, XM_011530244.1:c.78C>G, XM_011530245.1:c.78C>G, XP_005261710.1:p.Leu162Val, XP_005261711.1:p.Leu162Val, XP_005261712.1:p.Leu162Val, XP_005261713.1:p.Leu162Val, XP_005261714.1:p.Leu162Val, XP_005261715.1:p.Leu162Val, XP_006724332.1:p.Leu162Val, XP_006724333.1:p.Leu162Val, XP_011528541.1:p.Leu162Val, XP_011528542.1:p.Leu162Val, XP_011528543.1:p.Leu162Val, XP_011528544.1:p.Leu162Val, XP_011528545.1:p.Leu162Val, XP_011528546.1:p.Ala26=, XP_011528547.1:p.Ala26=, XR_244379.1:n.707C>G, XR_937869.1:n.799C>G, XR_937870.1:n.798C>G, rs17248699, rs4253796, rs59477602
C > G
SNP
L162V
No VIP available CA VA
rs1800795 NC_000007.13:g.22766645C>G, NC_000007.14:g.22727026C>G, NG_011640.1:g.4880C>G, NM_000600.4:c.-237C>G, NM_001318095.1:c.-274C>G, NR_131935.1:n.54-321G>C, XM_005249745.1:c.-237C>G, XM_005249745.3:c.-237C>G, XM_005249746.1:c.-274C>G, XM_011515390.1:c.-84-153C>G, XM_011515391.1:c.-274C>G, rs17777058, rs36215460, rs56588968, rs58302852
C > G
SNP
No VIP available No Clinical Annotations available VA
rs1801177 NC_000008.10:g.19805708G>A, NC_000008.11:g.19948197G>A, NG_008855.1:g.14127G>A, NM_000237.2:c.106G>A, NP_000228.1:p.Asp36Asn, rs386481815, rs52806281
G > A
SNP
D36N
No VIP available CA VA
rs2230806 NC_000009.11:g.107620867C>T, NC_000009.12:g.104858586C>T, NG_007981.1:g.74570G>A, NM_005502.3:c.656G>A, NP_005493.2:p.Arg219Lys, XM_005251773.1:c.656G>A, XM_005251774.1:c.656G>A, XM_005251775.1:c.593G>A, XM_005251776.1:c.476G>A, XM_005251777.1:c.656G>A, XM_005251778.1:c.656G>A, XM_005251780.1:c.656G>A, XM_011518339.1:c.731G>A, XM_011518340.1:c.731G>A, XM_011518341.1:c.731G>A, XM_011518342.1:c.293G>A, XM_011518343.1:c.731G>A, XM_011518344.1:c.731G>A, XP_005251830.1:p.Arg219Lys, XP_005251831.1:p.Arg219Lys, XP_005251832.1:p.Arg198Lys, XP_005251833.1:p.Arg159Lys, XP_005251834.1:p.Arg219Lys, XP_005251835.1:p.Arg219Lys, XP_005251837.1:p.Arg219Lys, XP_011516641.1:p.Arg244Lys, XP_011516642.1:p.Arg244Lys, XP_011516643.1:p.Arg244Lys, XP_011516644.1:p.Arg98Lys, XP_011516645.1:p.Arg244Lys, XP_011516646.1:p.Arg244Lys, rs2234884, rs2853572, rs52801000, rs61696010
C > T
SNP
R219K
No VIP available CA VA
rs2230808 NC_000009.11:g.107562804T>C, NC_000009.12:g.104800523T>C, NG_007981.1:g.132633A>G, NM_005502.3:c.4760A>G, NP_005493.2:p.Lys1587Arg, XM_005251773.1:c.4766A>G, XM_005251774.1:c.4766A>G, XM_005251775.1:c.4703A>G, XM_005251776.1:c.4586A>G, XM_005251777.1:c.4766A>G, XM_005251778.1:c.4766A>G, XM_005251779.1:c.3944A>G, XM_005251780.1:c.4766A>G, XM_011518339.1:c.4841A>G, XM_011518340.1:c.4841A>G, XM_011518341.1:c.4835A>G, XM_011518342.1:c.4403A>G, XM_011518343.1:c.4841A>G, XP_005251830.1:p.Lys1589Arg, XP_005251831.1:p.Lys1589Arg, XP_005251832.1:p.Lys1568Arg, XP_005251833.1:p.Lys1529Arg, XP_005251834.1:p.Lys1589Arg, XP_005251835.1:p.Lys1589Arg, XP_005251836.1:p.Lys1315Arg, XP_005251837.1:p.Lys1589Arg, XP_011516641.1:p.Lys1614Arg, XP_011516642.1:p.Lys1614Arg, XP_011516643.1:p.Lys1612Arg, XP_011516644.1:p.Lys1468Arg, XP_011516645.1:p.Lys1614Arg, rs2234886, rs57688810
T > C
SNP
K1587R
No VIP available CA VA
rs2241883 NC_000002.11:g.88424066T>C, NC_000002.12:g.88124547T>C, NM_001443.2:c.280A>G, NP_001434.1:p.Thr94Ala, rs59305633
T > C
SNP
T94A
No VIP available No Clinical Annotations available VA
rs2542051 NC_000011.10:g.116827022C>A, NC_000011.9:g.116697738C>A, NG_008949.1:g.2115C>A, NG_012044.1:g.1274G>T, rs35585311
C > A
SNP
No VIP available No Clinical Annotations available VA
rs2542052 NC_000011.10:g.116829268A>C, NC_000011.9:g.116699984A>C, NG_008949.1:g.4361A>C, NM_000040.1:c.-686A>C, rs17257727, rs45473900, rs55910034
A > C
SNP
No VIP available No Clinical Annotations available VA
rs2727784 NC_000011.10:g.116840425C>T, NC_000011.9:g.116711141C>T, NG_012021.1:g.2198G>A, NR_126362.1:n.123+4186C>T, rs3758982
C > T
SNP
No VIP available CA VA
rs2727786 NC_000011.10:g.116837807C>G, NC_000011.9:g.116708523C>G, NG_012021.1:g.4816G>C, NM_000039.2:c.-223G>C, NM_001318017.1:c.-300G>C, NM_001318018.1:c.-269G>C, NM_001318021.1:c.-506G>C, NR_126362.1:n.123+1568C>G, XM_005271539.1:c.-269G>C, XM_005271539.2:c.-269G>C, XM_005271540.1:c.-300G>C
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2854116 NC_000011.10:g.116829453C>T, NC_000011.9:g.116700169C>T, NG_008949.1:g.4546C>T, NM_000040.1:c.-501C>T, rs17251249, rs35523410, rs45537037
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2854117 NC_000011.10:g.116829426T>C, NC_000011.9:g.116700142T>C, NG_008949.1:g.4519T>C, NM_000040.1:c.-528T>C, rs17251242, rs33989105
T > C
SNP
No VIP available CA VA
rs3091244 NC_000001.10:g.159684665G>A, NC_000001.11:g.159714875G>A, NG_013007.1:g.4715C>T, NM_000567.2:c.-390C>T, XM_005244904.1:c.-390C>T, XM_011509207.1:c.-390C>T, rs117342995, rs17860484, rs386579141, rs59168471
G > A
G > T
SNP
No VIP available No Clinical Annotations available VA
rs3093059 NC_000001.10:g.159685136A>G, NC_000001.11:g.159715346A>G, NG_013007.1:g.4244T>C, NM_000567.2:c.-861T>C, XM_005244904.1:c.-861T>C, XM_011509207.1:c.-861T>C, rs16842586, rs17860487, rs386579163
A > G
SNP
No VIP available CA VA
rs3135506 NC_000011.10:g.116791691G>C, NC_000011.9:g.116662407G>C, NG_015894.1:g.5730C>G, NM_001166598.1:c.56C>G, NM_052968.4:c.56C>G, NP_001160070.1:p.Ser19Trp, NP_443200.2:p.Ser19Trp, rs28939090
G > C
SNP
S19W
No VIP available CA VA
rs320 NC_000008.10:g.19819077T>G, NC_000008.11:g.19961566T>G, NG_008855.1:g.27496T>G, NM_000237.2:c.1322+483T>G
T > G
SNP
No VIP available CA VA
rs4238001 NC_000012.11:g.125348263C>T, NC_000012.12:g.124863717C>T, NG_028199.1:g.5257G>A, NM_001082959.1:c.4G>A, NM_005505.4:c.4G>A, NP_001076428.1:p.Gly2Ser, NP_005496.4:p.Gly2Ser, XM_005253633.1:c.4G>A, XM_005253636.1:c.4G>A, XP_005253690.1:p.Gly2Ser, XP_005253693.1:p.Gly2Ser, XR_945488.1:n.-1802C>T
C > T
SNP
G2S
No VIP available CA VA
rs4253778 NC_000022.10:g.46630634G>C, NC_000022.11:g.46234737G>C, NG_012204.1:g.89136G>C, NM_001001928.2:c.1160-396G>C, NM_005036.4:c.1160-396G>C, XM_005261653.1:c.1160-396G>C, XM_005261654.1:c.1160-396G>C, XM_005261655.1:c.1160-396G>C, XM_005261655.2:c.1160-396G>C, XM_005261656.1:c.1160-396G>C, XM_005261656.2:c.1160-396G>C, XM_005261657.1:c.1160-396G>C, XM_005261658.1:c.1160-396G>C, XM_006724269.2:c.1160-396G>C, XM_006724270.2:c.1160-396G>C, XM_011530239.1:c.1160-396G>C, XM_011530240.1:c.1160-396G>C, XM_011530241.1:c.1160-396G>C, XM_011530242.1:c.1160-396G>C, XM_011530243.1:c.1160-396G>C, XM_011530244.1:c.758-396G>C, XM_011530245.1:c.758-396G>C, XR_244379.1:n.1184-396G>C, XR_937869.1:n.1276-396G>C, XR_937870.1:n.1271-396G>C, rs17248629, rs57323063, rs61046783
G > C
SNP
No VIP available No Clinical Annotations available VA
rs4520 NC_000011.10:g.116830819T>C, NC_000011.9:g.116701535T>C, NG_008949.1:g.5912T>C, NM_000040.1:c.102T>C, NP_000031.1:p.Gly34=, rs1049040, rs17251277, rs3168250, rs61905138, rs734105
T > C
SNP
G34G
No VIP available No Clinical Annotations available VA
rs5090 NC_000011.10:g.116823339C>G, NC_000011.9:g.116694055C>G, NG_012044.1:g.4957G>C, NM_000482.3:c.-148G>C, rs17244652
C > G
SNP
No VIP available No Clinical Annotations available VA
rs5092 NC_000011.10:g.116822748C>T, NC_000011.9:g.116693464C>T, NG_012044.1:g.5548G>A, NM_000482.3:c.87G>A, NP_000473.2:p.Thr29=, rs17244645
C > T
SNP
T29T
No VIP available No Clinical Annotations available VA
rs5104 NC_000011.10:g.116821618C>T, NC_000011.9:g.116692334C>T, NG_012044.1:g.6678G>A, NM_000482.3:c.440G>A, NP_000473.2:p.Ser147Asn, rs17244617, rs61905135
C > T
SNP
S147N
No VIP available No Clinical Annotations available VA
rs5128 NC_000011.10:g.116832924G>C, NC_000011.9:g.116703640G>C, NG_008949.1:g.8017G>C, NM_000040.1:c.*40G>C, rs17257817, rs3168249, rs45487004
G > C
SNP
No VIP available No Clinical Annotations available VA
rs613808 NC_000011.10:g.116840252A>G, NC_000011.9:g.116710968A>G, NG_012021.1:g.2371T>C, NR_126362.1:n.123+4013A>G, rs3758983
A > G
SNP
No VIP available No Clinical Annotations available VA
rs662799 NC_000011.10:g.116792991G>A, NC_000011.9:g.116663707G>A, NG_015894.1:g.4430C>T, NM_001166598.1:c.-620C>T, NM_052968.4:c.-644C>T, rs3809039, rs60708336
G > A
SNP
No VIP available No Clinical Annotations available VA
rs670 NC_000011.10:g.116837697C>T, NC_000011.9:g.116708413C>T, NG_012021.1:g.4926G>A, NM_000039.2:c.-113G>A, NM_001318017.1:c.-190G>A, NM_001318018.1:c.-159G>A, NM_001318021.1:c.-396G>A, NR_126362.1:n.123+1458C>T, XM_005271539.1:c.-159G>A, XM_005271539.2:c.-159G>A, XM_005271540.1:c.-190G>A, rs17243116, rs61758319
C > T
SNP
No VIP available No Clinical Annotations available VA
rs675 NC_000011.10:g.116820959T>A, NC_000011.9:g.116691675T>A, NG_012044.1:g.7337A>T, NM_000482.3:c.1099A>T, NP_000473.2:p.Thr367Ser, rs17250988, rs45474794, rs52810209, rs9282882
T > A
SNP
T367S
No VIP available CA VA
rs676210 NC_000002.11:g.21231524G>A, NC_000002.12:g.21008652G>A, NG_011793.1:g.40422C>T, NM_000384.2:c.8216C>T, NP_000375.2:p.Pro2739Leu, XM_011532809.1:c.5869+2081C>T, rs117511753, rs17240903, rs52830519, rs60113879
G > A
SNP
P2739L
No VIP available No Clinical Annotations available VA
rs708272 NC_000016.10:g.56962376G>A, NC_000016.9:g.56996288G>A, NG_008952.1:g.5454G>A, NM_000078.2:c.118+279G>A, NM_001286085.1:c.118+279G>A, XM_005255776.1:c.118+279G>A, XM_006721124.2:c.118+279G>A, rs17237904, rs17290342, rs57207652
G > A
SNP
No VIP available No Clinical Annotations available VA
rs780094 NC_000002.11:g.27741237T>C, NC_000002.12:g.27518370T>C, NG_028024.1:g.26532T>C, NM_001486.3:c.1423-418T>C, XM_005264256.1:c.1417-418T>C, XM_005264257.1:c.1354-418T>C, XM_005264258.1:c.853-418T>C, XM_011532761.1:c.1270-418T>C, XM_011532762.1:c.853-418T>C, rs17705107, rs386613275, rs59441336
T > C
SNP
No VIP available CA VA
rs9626730 NC_000022.10:g.46562183T>C, NC_000022.11:g.46166284T>C, NG_012204.1:g.20685T>C, NM_001001928.2:c.-43+14310T>C, NM_005036.4:c.-126-10467T>C, XM_005261653.1:c.-43+14310T>C, XM_005261654.1:c.-40+14310T>C, XM_005261655.1:c.-126-10467T>C, XM_005261655.2:c.-126-10469T>C, XM_006724269.2:c.-123-10469T>C, XM_006724270.2:c.-40+14314T>C, XM_011530239.1:c.-223-10469T>C, XM_011530240.1:c.-226-10469T>C, XM_011530241.1:c.-140+14314T>C, XM_011530244.1:c.-632-10469T>C, XM_011530245.1:c.-449+14314T>C, XR_244379.1:n.181+14310T>C, XR_937869.1:n.190-10469T>C, XR_937870.1:n.189-10469T>C, XR_938315.1:n.249-4962A>G, rs11090773, rs35718056, rs52826906
T > C
SNP
No VIP available CA VA
rs964184 NC_000011.10:g.116778201G>C, NC_000011.9:g.116648917G>C, NM_001317086.1:c.*724C>G, NM_003904.4:c.*724C>G, rs12800211, rs17120026
G > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • FNF
  • Fenofibrato [INN-Spanish]
  • Fenofibratum [INN-Latin]
  • Finofibrate
  • fenofibric acid
Trade Names
  • Ankebin
  • Antara
  • Elasterate
  • Elasterin
  • Fenobrate
  • Fenogal
  • Fenotard
  • Lipanthyl
  • Lipantil
  • Lipidex
  • Lipidil
  • Lipidil Micro
  • Lipidil Supra
  • Lipifen
  • Lipirex
  • Lipoclar
  • Lipofene
  • Liposit
  • Lipsin
  • Lofibra
  • Luxacor
  • Nolipax
  • Procetofen
  • Proctofene
  • Protolipan
  • Secalip
  • Sedufen
  • Tricor
  • Triglide
  • Trilipix
Brand Mixture Names

PharmGKB Accession Id

PA449594

Type(s):

Drug

Description

An antilipemic agent which reduces both cholesterol and triglycerides in the blood.

Source: Drug Bank

Indication

For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly.

Source: Drug Bank

Pharmacology

Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.

Source: Drug Bank

Food Interaction

Increased absorption- take with meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Protein Binding

~99% (Serum protein binding)

Source: Drug Bank

Absorption

Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide

Source: Drug Bank

Half-Life

20 hours

Source: Drug Bank

Toxicity

LD 50=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.

Source: Drug Bank

Chemical Properties

Chemical Formula

C20H21ClO4

Source: Drug Bank

Isomeric SMILES

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl

Source: OpenEye

Canonical SMILES

CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1

Source: Drug Bank

Average Molecular Weight

360.831

Source: Drug Bank

Monoisotopic Molecular Weight

360.112836867

Source: Drug Bank

SMILES

CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1

Source: Drug Bank

InChI String

InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
PPARA (source: Drug Bank)

Drug Interactions

Interaction Description
atorvastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
atorvastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
cerivastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
cerivastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - acenocoumarol The fibrate increases the anticoagulant effect (source: Drug Bank)
fenofibrate - acenocoumarol Fenofibrate may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank)
fenofibrate - anisindione Fenofibrate may increase the anticoagulant effect of anisindione. (source: Drug Bank)
fenofibrate - atorvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - atorvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - cerivastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - cerivastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - dicumarol The fibrate increases the anticoagulant effect (source: Drug Bank)
fenofibrate - dicumarol Fenofibrate may increase the anticoagulant effect of dicumarol. (source: Drug Bank)
fenofibrate - fluvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - fluvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - lovastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - lovastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - rosuvastatin Rosuvastatin possibly increases the effect of the fibrate (source: Drug Bank)
fenofibrate - rosuvastatin Rosuvastatin may increase the effect of fenofibrate. (source: Drug Bank)
fenofibrate - simvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - simvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fenofibrate - ursodeoxycholic acid The fibric acid derivative decreases the effect of ursodiol (source: Drug Bank)
fenofibrate - warfarin The fibrate increases the anticoagulant effect (source: Drug Bank)
fenofibrate - warfarin Fenofibrate may increase the anticoagulant effect of warfarin. (source: Drug Bank)
fluvastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
fluvastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
lovastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
lovastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
pravastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
pravastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
warfarin - fenofibrate Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to fenofibrate: 22

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A family-specific linkage analysis of blood lipid response to fenofibrate in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenetics and genomics. 2015. Hidalgo Bertha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacoepidemiologic and in Vitro Evaluation of Potential Drug-Drug Interactions of Sulfonylureas with Fibrates and Statins. British journal of clinical pharmacology. 2014. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. The pharmacogenomics journal. 2012. Frazier-Wood A C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate. PloS one. 2012. Aslibekyan Stella, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. Journal of lipid research. 2010. Wojczynski Mary K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Molecular genetics and metabolism. 2010. Tsai Michael Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice. The pharmacogenomics journal. 2010. Sanoudou D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Medicinal Chemistry of Drugs used in Diabetic Cardiomyopathy. Current medicinal chemistry. 2009. Adeghate E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenetics and genomics. 2009. Liu Yongjun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common sequence variant in lipoprotein lipase gene conferring triglyceride response to fibrate treatment. Pharmacogenomics. 2009. Chien Kuo-Liong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. The American journal of clinical nutrition. 2009. Perez-Martinez Pablo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes care. 2008. Shen Jian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. Journal of human genetics. 2008. Liu Yongjun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. Journal of lipid research. 2007. Valasek Mark A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arteriosclerosis, thrombosis, and vascular biology. 2007. Lai Chao-Qiang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2006. Potaczek Daniel P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clinical pharmacokinetics. 2005. Kosoglou Teddy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004. Foucher Christelle, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. Journal of human genetics. 2004. Brouillette Charles, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics. 2002. Brisson Diane, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0378-7100-77
DrugBank:
DB01039
ChEBI:
5001
KEGG Compound:
C07586
KEGG Drug:
D00565
PubChem Compound:
3339
PubChem Substance:
180502
46507371
Drugs Product Database (DPD):
2250039
ChemSpider:
3222
Therapeutic Targets Database:
DAP000270
FDA Drug Label at DailyMed:
c53c20ed-a944-4b35-b5db-91d9f67240e8

Clinical Trials

These are trials that mention fenofibrate and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.